Dr. Steve Kheloussi (Highmark, Inc.) and Dana McCormick (BlueCross BlueShield Texas) delve into the complexities health plans face in managing treatments for atopic dermatitis. They explore innovative treatment options that have recently become available, the impact of these treatments on patient quality of life, and strategies health plans can implement to enhance patient outcomes. The conversation highlights the challenges in designing benefits to ensure timely access to evidence-based treatments, the lag in clinical guidelines following rapid advancements in therapy options, and the administrative hurdles that can impede patient care. The faculty also discuss the importance of payer-provider collaboration in addressing these issues and the potential for technology to streamline access and reduce administrative burdens. This discussion is essential for health plan professionals looking to navigate the intricacies of providing coverage for atopic dermatitis treatments effectively.

This activity is certified for CME/CNE/CPE credit. To participate and earn credit, visit us at https://www.impactedu.net/atopicdermstrategies/.

In this award-winning episode hosted by Dr. Steven Kheloussi (Highmark, Inc.) and featuring guest Ashley Ellis (National Eczema Association), the dialogue revolves around the multifaceted challenges presented by atopic dermatitis. Ashley shares her personal journey as a mother of a child with atopic dermatitis, providing insights into the patient and caregiver experience. The discussion covers the clinical management of the condition, its economic implications for families, and the broader humanistic impact on patients' lives, emphasizing the need for empathy and understanding in healthcare interactions. The conversation also touches on the importance of effective patient-provider communication, the potential benefits of newer treatment options, and the complexities involved in navigating health insurance systems to access necessary care.

This activity is certified for CME/CNE/CPE credit. To participate and earn credit, visit us at https://www.impactedu.net/atopicdermburden/. 

This podcast features discussions on the impact of real-time continuous glucose monitoring (CGM) on glycemic control and acute metabolic events among insulin-treated diabetes patients. Dr. Jeffrey Dunn (Cooperative Benefits Group) and Dr. Richard Dlott (formerly The Permanente Medical Group (TPMG) / Kaiser Permanente Northern California) look at the findings of a recent study published in JAMA, which observed significant benefits of CGM in both type 1 and type 2 diabetes patients, including notable A1c reductions and decreased emergency room visits for hypoglycemia. They emphasize the importance of patient engagement in diabetes management and explore the implications of new CMS quality measures for 2023 on health plans. The conversation highlights the potential for CGM to transform diabetes care by providing real-time data that can empower patients and inform treatment decisions, underscoring the need for health plans to consider broader access to this technology.

This activity is certified for CME/CNE/CPE credit. To participate and earn credit, visit us at https://www.managedcarecgm.com/impactpayertalk/. 

In this podcast, Dr. Jeff Dunn (Cooperative Benefits Group) and Estay Greene, PharmD, MBA (Zing Health), explore effective strategies for enhancing diabetes care among underserved populations, particularly the elderly. They discuss the importance of addressing hypoglycemia risks and the integration of continuous glucose monitoring (CGM) to improve patient outcomes. The dialogue sheds light on the challenge of balancing cost-effective treatment with the safety and efficacy of diabetes management, emphasizing the need for health plans to adapt to innovative technologies and education for better patient engagement. They highlight how Zing Health is pioneering in providing CGM devices at no cost to members and the impact of recent CMS coverage changes on diabetes care. The session concludes with insights into tackling technology gaps in elderly patients and addressing disparities in diabetes treatment across different demographics.

This activity is certified for CME/CNE/CPE credit. To participate and earn credit, visit us at https://www.managedcarecgm.com/cgmqualitypayertalk/.

In this award-winning podcast, Dr. Roy Gandolfi (SelectHealth) and Dr. Jeff Dunn (Cooperative Benefits Group) discuss the integration and benefits of real-time continuous glucose monitoring (rtCGM) in managing diabetes, particularly through Medicare Advantage. They examine the clinical evidence supporting rtCGM's role in improving patient outcomes, adherence to ADA guidelines, and recent CMS local coverage determination criteria updates facilitating broader rtCGM access. The conversation emphasizes rtCGM's potential in enhancing patient engagement, reducing healthcare costs, and improving quality metrics. A Q&A session with the audience addresses CMS changes, health plan coverage, and identifying rtCGM candidates, underscoring the technology's growing impact on diabetes care.

This activity is certified for CME/CNE/CPE credit. To participate and earn credit, visit us at https://www.managedcarecgm.com/rtcgmrecommendations/. 

In this PayerTalkCE" podcast join host Dr. Steve Kheloussi (Highmark, Inc.) and guest Dr. Adam Friedman (The George Washington University School of Medicine and Health Sciences) and listen as their discussion explores the significant advancements in the treatment of atopic dermatitis. Dr. Friedman shares insights into the disease's complexities, its impact on quality of life, and the innovative therapies transforming patient care. The conversation delves into the challenges and opportunities health plans face in integrating these new treatments, emphasizing the need for personalized care and equitable access. This episode is an invaluable resource for health plan professionals seeking to enhance their understanding of atopic dermatitis and its evolving treatment landscape.

This activity is certified for CME/CNE/CPE credit. To participate and earn credit, visit us at https://www.impactedu.net/atopicdermpayertalk/.

This award-winning podcast explores the intricacies of managing and adopting oncology biosimilars, highlighting their crucial role in delivering cost-effective cancer care. The discussion involves experts who examine the regulatory landscape, share insights from real-world evidence, and discuss the clinical implications of biosimilars. Key topics include their efficacy, safety, and interchangeability. The conversation also covers the challenges and strategies for incorporating biosimilars into healthcare systems, emphasizing the need for education, policy adjustments, and practice adaptations. This dialogue aims to enhance health plan professionals' understanding and confidence in biosimilars, underlining their potential to expand patient access to treatments while achieving substantial healthcare savings. Featured faculty include Dr. Raj Duggal (Indiana University Health), Jim Kenney (formerly Harvard Pilgrim), and Dr. Cate Lockhart (Biologics and Biosimilars Collective Intelligence Consortium).

This activity is certified for CME/CNE/CPE credit. To participate and earn credit, visit us at https://www.impactedu.net/biosimpayertalk/.